The NHS is introducing a new way to administer the cancer drug pembrolizumab (Keytruda), aiming to speed up treatment for patients who are eligible for the therapy. Reporting from multiple outlets says the approach changes administration from an infusion that can take hours to a much shorter, one-minute injection. The articles state that tens of thousands of patients could benefit from the shorter treatment time. They also frame the update as part of efforts to improve the way cancer care is delivered, potentially reducing time spent in clinical settings while patients receive the medicine. Both sources describe pembrolizumab as the drug at the centre of the change and note that the prior method required lengthy infusion sessions. The coverage focuses on the expected scale of impact, with the NHS planning for a large number of patients rather than a small pilot group, and presents the development as a notable operational shift within cancer services. Details about eligibility criteria, rollout timelines, and how the new method is implemented are not included in the provided excerpts.